{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:28:49Z","timestamp":1776356929812,"version":"3.51.2"},"reference-count":21,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>This meta-analysis aims to assess the efficacy and safety of tedizolid, compared to linezolid, in the treatment of acute bacterial skin and skin structure infection (ABSSSI). PubMed, Web of Science, EBSCO (Elton B. Stephens Co.), Cochrane Library, Ovid Medline and Embase databases were accessed until 18 July 2019. Only randomized controlled trials (RCTs) comparing the efficacy of tedizolid with linezolid for adult patients with ABSSSIs were included. The outcomes included the clinical response, microbiological response, and risk of adverse events (AEs). A total of four RCTs involving 2056 adult patients with ABSSSI were enrolled. The early clinical response rate was 79.6% and 80.5% for patients receiving tedizolid and linezolid, respectively. The pooled analysis showed that tedizolid had a non-inferior early clinical response rate to linezolid (odds ratio (OR) = 0.96, 95% confidence interval (CI) = 0.77\u20131.19, I2 = 0%). The early response rate was similar between tedizolid and linezolid among patients with cellulitis\/erysipelas (75.1% vs. 77.1%; OR = 0.90, 95% CI = 0.64\u20131.27, I2 = 25%), major cutaneous abscess (85.1% vs. 86.8%; OR = 0.93, 95% CI = 0.42\u20132.03, I2 = 37%) and wound infection (85.9% vs. 82.6%; OR = 1.29, 95% CI = 0.66\u20132.51, I2 = 45%). For methicillin-resistant Staphylococcus aureus patients, tedizolid had a favorable microbiological response rate of 95.2% which was comparable to linezolid (94%) (OR = 1.19, 95% CI = 0.49\u20132.90, I2 = 0%). In addition to the similar risk of treatment-emergent AEs (a serious event, the discontinuation of the study drug due to AEs and mortality between tedizolid and linezolid), tedizolid was associated with a lower risk of nausea, vomiting and abnormal neutrophil count than linezolid. In conclusion, once-daily tedizolid (200 mg for six days) compared to linezolid (600 mg twice-daily for 10 days) was non-inferior in efficacy in the treatment of ABSSSI. Besides, tedizolid was generally as well tolerated as linezolid, and had a lower incidence of gastrointestinal AEs and bone marrow suppression than linezolid.<\/jats:p>","DOI":"10.3390\/antibiotics8030137","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T03:22:36Z","timestamp":1567653756000},"page":"137","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8663-3161","authenticated-orcid":false,"given":"Shao-Huan","family":"Lan","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences and Medical Technology, Putian University, Putian 351100, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ting","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Orthopedic, Chi Mei Medical Center, Tainan 71004, Taiwan"},{"name":"Department of Physical Therapy, Shu Zen Junior College of Medicine and Management, Kaohsiung 82144, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen-Peng","family":"Chang","sequence":"additional","affiliation":[{"name":"Yijia Pharmacy, Tainan 70846, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Chin","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Management, Putian University, Putian 351100, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ming","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying 73657, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 71051, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jui-Hsiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infection Disease, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 71051, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E377","DOI":"10.1111\/1469-0691.12235","article-title":"Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010\u20132011): Assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study","volume":"19","author":"Garau","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s11739-016-1450-6","article-title":"Acute bacterial skin and skin structure infections in internal medicine wards: Old and new drugs","volume":"11","author":"Falcone","year":"2016","journal-title":"Intern. Emerg. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ray, G.T., Suaya, J.A., and Baxter, R. (2013). Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: A retrospective population-based study. BMC Infect. Dis., 13.","DOI":"10.1186\/1471-2334-13-252"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/QCO.0000000000000353","article-title":"The role of methicillin-resistant Staphylococcus aureus in skin and soft tissue infections","volume":"30","author":"Bassetti","year":"2017","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1469-0691.12463","article-title":"European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid","volume":"20","author":"Bassetti","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lan, S.H., Chang, S.P., Lai, C.C., Lu, L.C., and Chao, C.M. (2019). Ceftaroline efficacy and safety in treatment of complicated skin and soft tissue infection: A systemic review and meta-analysis of randomized controlled trials. J. Clin. Med., 8.","DOI":"10.3390\/jcm8060776"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QCO.0000000000000529","article-title":"Current role of oxazolidinones and lipoglycopeptides in skin and soft tissue infections","volume":"32","author":"Righi","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e02252-18","DOI":"10.1128\/AAC.02252-18","article-title":"Efficacy and safety of tedizolid phosphate versus linezolid in a randomized phase 3 trial in patients with acute bacterial skin and skin structure infection","volume":"63","author":"Lv","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jiac.2018.01.010","article-title":"Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan\u2014Results of a randomised, multicentre phase 3 study","volume":"24","author":"Mikamo","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): A randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/AAC.00076-10","article-title":"Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections","volume":"55","author":"Prokocimer","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: The ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.03688-14","article-title":"Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections","volume":"59","author":"Shorr","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e02687-16","DOI":"10.1128\/AAC.02687-16","article-title":"Clinical Response of Tedizolid versus linezolid in acute bacterial skin and skin structure infections by severity measure using a pooled analysis from two phase 3 double-blind trials","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7547\/15-218","article-title":"Tedizolid and linezolid for treatment of acute bacterial skin and skin structure infections of the lower extremity versus non-lower-extremity infections: Pooled analysis of two phase 3 trials","volume":"107","author":"Joseph","year":"2017","journal-title":"J. Am. Podiatr. Med. Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hasannejad-Bibalan, M., Mojtahedi, A., Biglari, H., Halaji, M., and Sedigh Ebrahim-Saraie, H. (2019). Antibacterial activity of tedizolid, a novel oxazolidinone against methicillin-resistant Staphylococcus aureus: A systematic review and meta-analysis. Microb. Drug Resist.","DOI":"10.1089\/mdr.2018.0457"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1089\/mdr.2018.0410","article-title":"In vitro activity of tedizolid in comparison with other oral and intravenous agents against a collection of community-acquired methicillin-resistant Staphylococcus aureus (2014\u20132015) in the United States","volume":"25","author":"Pfaller","year":"2019","journal-title":"Microb. Drug Resist."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bjid.2017.03.010","article-title":"In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid","volume":"21","author":"Urrego","year":"2017","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_21","first-page":"255","article-title":"Activity of linezolid and tedizolid against clinical isolates of methicillin-resistant and methicillin and linezolid resistant Staphylococcus aureus: An in vitro comparison","volume":"29","author":"Penuelas","year":"2016","journal-title":"Rev. Esp. Quimioter."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/8\/3\/137\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:16:39Z","timestamp":1760188599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/8\/3\/137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,4]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["antibiotics8030137"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics8030137","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,4]]}}}